# Belimumab After Rituximab in Resistant Primary Juvenile SS

> **NCT06410833** · PHASE4 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Sjogren's Syndrome
- Pediatric ALL

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Belimumab

## Key facts

- **NCT ID:** NCT06410833
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-09
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-05-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06410833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06410833, "Belimumab After Rituximab in Resistant Primary Juvenile SS". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06410833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*